Lessons from 60 years of pharmaceutical innovation

By B. Munos. Nature reviews. Drug discovery, 2009

1,147 citations recorded by the source corpus.

Subfields: Economics and Econometrics, Management of Technology and Innovation, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/d3ff29f6f34d8ad16cc5a1e69b46d4562029abdc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Economics and Econometrics

In Management of Technology and Innovation

In Public Health, Environmental and Occupational Health

Citations in the corpus

The Impact of Regulation on Innovation (2016, background): “However, besides the briefly described studies, further studies (Hart und Ahuja (1996), Pickman (1998), Brunnermeier and Cohen (2003), Popp et al.”
The future of molecular dynamics simulations in drug discovery (2011, background): “Productivity is one of the most signiﬁcant challenges facing the pharmaceutical industry, with $50 billion spent annually to produce only * 20 new drugs [6].”
Diagnosing the decline in pharmaceutical R&D efficiency (2012, background): “However, in parallel — as many have discussed — R&D efficiency, measured simply in terms of the number of new drugs brought to market by the global biotechnology and pharmaceutical industries per billion US dollars of R&D spending, has declined fairly steadil”
How were new medicines discovered? (2011, background): “jpg"/> Investment in drug research and development (R&D) has increased substantially in recent decades, but the annual number of truly innovative new medicines approved by the US Food and Drug Administration (FDA) has not increased accordingly, and attri”
Artificial intelligence and innovation management: A review, framework, and research agenda✰ (2021, background): “Drug development processes in the pharmaceutical industry show similar trends (Munos, 2009; Pammolli et al., 2011).”
The productivity crisis in pharmaceutical R&D (2011, background): “, while the rate of introduction of new molecular entities (NMEs) has at best remained approximately constan”